Drug intelligence / Profile preview

ME-344 + bevacizumab

Development stage: Unknown
Lead developer: MEI Pharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

ME-344 + bevacizumab is a combination therapy consisting of ME-344, a mitochondrial oxidative phosphorylation (OXPHOS) inhibitor, and bevacizumab (Avastin), an anti-angiogenic antibody. This combination creates metabolic synthetic lethality by leveraging the ability of bevacizumab to reduce glycolysis, forcing tumors to switch to mitochondrial respiration via OXPHOS, which is then inhibited by ME-344. The combination has shown promising results in clinical trials for metastatic colorectal cancer and HER2-negative breast cancer.

Brand names: Avastin

Targets

ND1 (Mitochondrial electron transport chain complex I)VEGFA (Vascular endothelial growth factor A)SDH (Mitochondrial electron transport chain complex II)

Beyond the preview

Go deeper on ME-344 + bevacizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ME-344 + bevacizumab.

Explore the full profile